CL2020000098A1 - Polypeptide molecule with enhanced dual specificity. - Google Patents

Polypeptide molecule with enhanced dual specificity.

Info

Publication number
CL2020000098A1
CL2020000098A1 CL2020000098A CL2020000098A CL2020000098A1 CL 2020000098 A1 CL2020000098 A1 CL 2020000098A1 CL 2020000098 A CL2020000098 A CL 2020000098A CL 2020000098 A CL2020000098 A CL 2020000098A CL 2020000098 A1 CL2020000098 A1 CL 2020000098A1
Authority
CL
Chile
Prior art keywords
cells
specific
polypeptide molecule
dual specificity
polypeptide chain
Prior art date
Application number
CL2020000098A
Other languages
Spanish (es)
Inventor
Dominik Maurer
Sebastian Bunk
Martin Hofmann
Felix Unverdorben
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102017115966.5A external-priority patent/DE102017115966A1/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of CL2020000098A1 publication Critical patent/CL2020000098A1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA MOLÉCULA DE POLIPÉPTIDO BIESPECÍFICA QUE COMPRENDE UNA PRIMERA CADENA POLIPEPTÍDICA Y UNA SEGUNDA CADENA POLIPEPTÍDICA QUE PROPORCIONA UNA REGIÓN DE UNIÓN DERIVADA DE UN RECEPTOR DE LINFOCITO T (TCR) QUE ES ESPECÍFICA PARA UN EPÍTOPO PEPTÍDICO ASOCIADO AL COMPLEJO PRINCIPAL DE HISTOCOMPATIBILIDAD (MHC), Y UNA REGIÓN DE UNIÓN DERIVADA DE UN ANTICUERPO CAPAZ DE RECLUTAR CÉLULAS EFECTORAS INMUNITARIAS HUMANAS MEDIANTE LA UNIÓN ESPECÍFICA A UN ANTÍGENO DE SUPERFICIE DE DICHAS CÉLULAS, ASÍ COMO MÉTODOS PARA FABRICAR LA MOLÉCULA DE POLIPÉPTIDO BIESPECÍFICA, Y USOS DE LA MISMA.THE PRESENT INVENTION REFERS TO A BI-SPECIFIC POLYPEPTIDE MOLECULE THAT COMPRISES A FIRST POLYPEPTIDE CHAIN AND A SECOND POLYPEPTIDE CHAIN THAT PROVIDES A BINDING REGION DERIVED FROM A TYPICAL LYMPHOCYTE RECEPTOR (TCR) WHICH IS SPECIFIC TO THE ASCIOPY LYMPHOCYTE PRINCIPLE OF THE PEPIPHEAL PEPIPSE HISTOCOMPATIBILITY (MHC), AND A REGION OF UNION DERIVED FROM AN ANTIBODY CAPABLE OF RECRUITING HUMAN IMMUNE EFFECTIVE CELLS THROUGH THE SPECIFIC BINDING TO A SURFACE ANTIGEN OF SAID CELLS, AS WELL AS MISCELLANEOUS MULTIPLE MULTIPLE CELLS, FOR THE MISCELLANEOUS MULTIPLE POLYESE .

CL2020000098A 2017-07-14 2020-01-13 Polypeptide molecule with enhanced dual specificity. CL2020000098A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762532713P 2017-07-14 2017-07-14
DE102017115966.5A DE102017115966A1 (en) 2017-07-14 2017-07-14 Polypeptide molecule with improved dual specificity
DE102017119866 2017-08-30
US201862658318P 2018-04-16 2018-04-16
DE102018108995 2018-04-16

Publications (1)

Publication Number Publication Date
CL2020000098A1 true CL2020000098A1 (en) 2020-05-29

Family

ID=70848164

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2020000097A CL2020000097A1 (en) 2017-07-14 2020-01-13 Polypeptide molecule with enhanced dual specificity.
CL2020000098A CL2020000098A1 (en) 2017-07-14 2020-01-13 Polypeptide molecule with enhanced dual specificity.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2020000097A CL2020000097A1 (en) 2017-07-14 2020-01-13 Polypeptide molecule with enhanced dual specificity.

Country Status (6)

Country Link
JP (1) JP2021019626A (en)
CL (2) CL2020000097A1 (en)
HR (1) HRP20210759T1 (en)
IL (2) IL272046A (en)
PH (2) PH12020500098A1 (en)
ZA (1) ZA202000636B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015012709A (en) * 2013-03-14 2016-05-31 Macrogenics Inc Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor.

Also Published As

Publication number Publication date
PH12020500095A1 (en) 2020-12-07
HRP20210759T1 (en) 2021-06-11
PH12020500098A1 (en) 2020-12-07
CL2020000097A1 (en) 2020-05-29
IL272045A (en) 2020-03-31
IL272046A (en) 2020-03-31
JP2021019626A (en) 2021-02-18
ZA202000636B (en) 2021-07-28

Similar Documents

Publication Publication Date Title
CO2020001491A2 (en) Polypeptide molecule with enhanced dual specificity
AR110676A1 (en) TREATMENT OF CANCER USING CHEMERIC ANTIGENS RECEPTORS
CO2018001405A2 (en) Chimeric antigen receptor based on single domain antibodies
CL2018000461A1 (en) Bispecific antibodies with tetravalence for a co-stimulator fnt receptor.
GT201700162A (en) ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES AND BIESPECIFIC ANTIBODIES THAT SPECIFICALLY JOIN CD3 AND / OR CD123
DOP2019000253A (en) ANTI-ILT4 ANTIBODIES AND ANTIGEN BINDING FRAGMENTS
BR112019007288A2 (en) bispecific heterodimeric protein, nucleic acid and expression vector compositions, expression vector, host cell, and methods for producing bispecific heterodimeric protein and for treating cancer in a patient
CO2017006808A2 (en) Bcma chimeric antigen receptors
CO2017010190A2 (en) Cd20 therapies, cd22 therapies and combination therapies with a cell that expresses a chimeric antigen (car) receptor of cd19
CO2017000506A2 (en) Chimeric cll-1 antigen receptor
AR104718A1 (en) RECEIVERS OF ANTI-GD3 SPECIFIC CHEMICAL ANTIGENS FOR IMMUNOTHERAPIES AGAINST CANCER
EA201792467A1 (en) HETERODIMERNYE ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
BR112018014760A2 (en) anti-ror1 antibodies, bispecific antibodies to ror1 x cd3 and methods of use
AR105433A1 (en) METHODS TO IMPROVE THE EFFECTIVENESS AND EXPANSION OF IMMUNE CELLS
UY35468A (en) CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
UY36289A (en) MONOCLONAL ANTIBODIES THAT IMMUNE SPECIFICALLY LINK TO CD123 and COMPOSITIONS THAT CONTAIN THEM
BR112016022369A2 (en) cd33-specific chimeric antigen receptors for cancer immunotherapy
BR112021016984A2 (en) dll3-targeted chimeric antigen receptors and binding agents
CR20140406A (en) ANTIBODIES CD47 AND METHODS OF USE OF THE SAME
GT201300233A (en) RECEIVERS OF SIMILAR T-CELLS TO SPECIFIC ANTIBODIES FOR A WT1 PEPTIDE PRESENTED BY HLA-A2
CL2018003515A1 (en) Anti-gitr antibodies and their uses.
BR112022024228A2 (en) CONSTRUCTS FOR CHIMERIC ANTIGEN RECEPTORS
CO2020014343A2 (en) Cd3-specific antibodies and their uses
CO2019003759A2 (en) Antibodies that bind to the zika virus envelope protein and uses thereof
AR112228A1 (en) POLYPEPTIDE MOLECULE WITH ENHANCED DUAL SPECIFICITY